We are live on
!
Find out more
Westfield Capital Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
49.45%
This Fund
S&P 500
This Quarter
Est. Return
+9.23%
1 Year Est. Return
+49.45%
3 Year Est. Return
+148.08%
5 Year Est. Return
+180.9%
10 Year Est. Return
+972.69%
AUM
$14.9B
AUM Growth
+$734M
(+5.2%)
Cap. Flow
-$271M
Cap. Flow
% of AUM
-1.83%
Top 10 Holdings %
Top 10 Hldgs %
17.52%
Holding
304
New
43
Increased
101
Reduced
105
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$215M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$184M |
| 3 |
Microsoft
MSFT
|
+$163M |
| 4 |
Biogen
BIIB
|
+$147M |
| 5 |
Synchrony
SYF
|
+$124M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$236M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$227M |
| 3 |
AbbVie
ABBV
|
+$169M |
| 4 |
Yum! Brands
YUM
|
+$147M |
| 5 |
Analog Devices
ADI
|
+$129M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.21% |
| 2 | Technology | 15.59% |
| 3 | Consumer Discretionary | 15.51% |
| 4 | Communication Services | 11.55% |
| 5 | Industrials | 11.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Citigroup
C
$224B
| $4.16M | 0.03% |
80,300
-45,050
| -36% | -$2.39M |
|
227
Upbound Group
UPBD
$1.14B
| $4.13M | 0.03% |
276,120
-745,230
| -73% | -$14.2M |
|
228
iShares Russell 1000 Growth ETF
IWF
$127B
| $3.9M | 0.03% |
+156,620
| New | +$3.91M |
|
229
3M
MMM
$93.2B
| $3.4M | 0.02% |
27,026
+24,761
| +1,093% | +$3.18M |
|
230
Lockheed Martin
LMT
$135B
| $3.14M | 0.02% |
14,450
+13,300
| +1,157% | +$2.89M |
|
231
Prothena Corp
PRTA
$449M
| $3.12M | 0.02% |
45,830
-942,149
| -95% | -$56.8M |
|
232
Danaher
DHR
$141B
| $2.39M | 0.02% |
38,349
-1,263
| -3% | -$79.1K |
|
233
iShares Core S&P US Growth ETF
IUSG
$33.4B
| $2.11M | 0.01% |
51,930
+17,154
| +49% | +$698K |
|
|
234
AbbVie
ABBV
$431B
| $2.1M | 0.01% |
35,375
-2,935,101
| -99% | -$169M |
|
235
Copart
CPRT
$26.9B
| $1.97M | 0.01% |
414,520
-358,360
| -46% | -$1.66M |
|
236
Allison Transmission
ALSN
$9.6B
| $1.96M | 0.01% |
75,550
| – | – |
|
237
CVS Health
CVS
$123B
| $1.94M | 0.01% |
19,800
-6,900
| -26% | -$676K |
|
238
State Street
STT
$50.8B
| $1.52M | 0.01% |
22,945
-1,794,370
| -99% | -$125M |
|
239
GE Aerospace
GE
$389B
| $1.37M | 0.01% |
9,202
| – | – |
|
240
Williams-Sonoma
WSM
$29.1B
| $1.34M | 0.01% |
45,794
-1,023,724
| -96% | -$35.1M |
|
241
Johnson & Johnson
JNJ
$619B
| $1.16M | 0.01% |
11,265
| – | – |
|
242
ExxonMobil
XOM
$642B
| $1.13M | 0.01% |
14,526
| – | – |
|
243
Merck
MRK
$317B
| $1.04M | 0.01% |
20,603
| – | – |
|
244
Northern Trust
NTRS
$33.7B
| $872K | 0.01% |
12,096
| – | – |
|
245
Packaging Corp of America
PKG
$22.5B
| $858K | 0.01% |
13,610
| – | – |
|
246
State Street SPDR S&P Regional Banking ETF
KRE
$4.65B
| $840K | 0.01% |
20,050
| – | – |
|
|
WCN
247
Waste Connections
WCN
$42.2B
| $824K | 0.01% |
21,938
| – | – |
|
|
CB
248
DELISTED
CHUBB CORPORATION
CB
| $634K | ﹤0.01% |
4,779
| – | – |
|
|
BEAT
249
DELISTED
BioTelemetry, Inc.
BEAT
| $585K | ﹤0.01% |
50,100
| – | – |
|
|
250
Vertex Pharmaceuticals
VRTX
$123B
| $566K | ﹤0.01% |
4,495
-1,957,104
| -100% | -$236M |
|
Similar funds
OAG
JG
CHP
SC
Westfield Capital Management's Q4 2015 Portfolio in Review
As of Q4 2015, Westfield Capital Management held 304 positions worth $14.9B, up 5.2% from $14.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Westfield Capital Management's Q4 2015 filing shows 43 new, 101 increased, 105 reduced and 32 closed positions. Its largest new stake was Alphabet (Google) Class A: 5,804,860 shares worth $226M. The largest sale was Vertex Pharmaceuticals, an estimated $236M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 20% a quarter earlier, followed by Technology and Consumer Discretionary.
- Westfield Capital Management's largest Q4 2015 buy was Alphabet (Google) Class A: 5,804,860 shares worth $226M.
- Westfield Capital Management added most to Bristol-Myers Squibb in Q4 2015, an estimated $184M increase.
- Westfield Capital Management's biggest Q4 2015 reduction was Vertex Pharmaceuticals, cutting an estimated $236M.
- Westfield Capital Management fully exited Analog Devices in Q4 2015, selling an estimated $129M.
- Westfield Capital Management's ten largest holdings make up 18% of its $14.9B portfolio in Q4 2015.
- Westfield Capital Management opened 43 new positions and closed 32 in Q4 2015.
- Westfield Capital Management's portfolio value rose 5.2% quarter-over-quarter to $14.9B.
Based on Westfield Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.